证券代码：688067 证券简称：爱威科技 公告编号：2025-024 爱威科技股份有限公司 第五届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会召开情况 爱威科技股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日召开第五 届监事会第四次会议，本次会议应出席监事 3 人，实际出席监事 3 人。会议由 监事会主席段小霞女士主持，以现场方式召开。本次会议的通知、召开及审议 程序符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于使用部分暂时闲置募集资金进行现金管理的议案》 议案内容详见公司同日刊载于上海证券交易所网站（www.sse.com.cn）的 《爱威科技股份有限公司关于使用部分暂时闲置募集资金进行现金管理的公 告》。 监事会认为：公司本次使用部分暂时闲置募集资金进行现金管理，用于购 买安全性高、流动性好、满足保本要求的现金管理产品,是在符合国家相关法律 法规要求、确保不影响公司募集资金投资进度、有效控制投资风险的前提 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology in the medical device industry, noting its current stock price and valuation metrics [1][2] - As of July 1, Aiwei Technology's stock closed at 21.76 yuan, with a PE ratio of 61.42, marking a new low in 349 days and a total market capitalization of 1.48 billion yuan [1] - The average PE ratio for the medical device industry is 51.70, with a median of 37.36, positioning Aiwei Technology at 92nd in the industry ranking [1][2] Group 2 - For Q1 2025, Aiwei Technology reported revenue of 53.30 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.32 million yuan, up 24.63% [2] - The company's gross profit margin stands at 55.59% [2] - As of March 31, 2025, Aiwei Technology had 3,605 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

证券代码：688067 证券简称：爱威科技 公告编号：2025-023 爱威科技股份有限公司 关于取得专利证书、软件著作权证书的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司（以下简称"公司"）及其子公司自 2025 年 1 月 1 日起至 2025 年 6 月 30 日 取得境内专利证书 9 项，其中发明专利 1 项、实用 新型专利 5 项、外观设计专利 3 项；取得境外专利 2 项；取得计算机软件著作 权登记证书 4 项。具体情况如下： （二）境外专利 序号 名称 国家 申请日 申请号 授权公开号 授权公开日 1 一种富集器、富集系 统、样本制造系统和 样本检测系统 美国 2019.12.17 17/779,708 US12292364B2 2025.05.06 2 一种富集器、富集系 统、样本制造系统和 样本检测系统 欧洲 2019.12.17 19953941.2 4050336 2025.04.30 （一）境内专利 1 上述专利的取得是公司重要核心技术的体现和延伸，本次专利 ...

为了规范募集资金的管理和使用，保护投资者权益，公司根据《上海证券交 易所科创板股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定和要求，结合公司实际情况，制定了《募集资金管 理制度》，对募集资金的存储、使用及管理等方面做出了明确的规定，在制度上 保证募集资金的规范使用。 为规范公司募集资金管理和使用，保护投资者权益，公司设立了相关募集资 金专户。募集资金到账后，已全部存放于募集资金专户内，公司及全资子公司湖 南爱威医疗科技有限公司(以下简称"爱威医疗")已与保荐机构西部证券股份有 限公司、存放募集资金的商业银行签署了募集资金三方/四方监管协议。上述募 1 集资金专户存储三方/四方监管协议与上海证券交易所《募集资金专户存储三方 监管协议（范本）》不存在重大差异，公司在使用募集资金时已经严格遵照执行。 证券代码：688067 证券简称：爱威科技 公告编号：2025-022 爱威科技股份有限公司 关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大 ...

Summary of Key Points Core Viewpoint - The company announced the cancellation of certain fundraising special accounts, reallocating the remaining funds to supplement its working capital permanently, following the completion of specific investment projects [1][3][4]. Fundraising Overview - The company was approved by the China Securities Regulatory Commission to issue 17 million shares at a price of 14.71 yuan per share, raising a total of 250,070,000 yuan, with the actual net amount being confirmed through an audit report [1][2]. Fund Management and Usage - To ensure proper management and usage of the raised funds, the company established special accounts and signed tripartite/quadripartite supervision agreements with its underwriter and the banks holding the funds [2][3]. - The company has implemented a fundraising management system to regulate the storage, usage, and management of the funds, ensuring compliance with relevant regulations [1][2]. Cancellation of Fundraising Accounts - The company decided to cancel two fundraising special accounts at Shanghai Pudong Development Bank due to the completion of the related investment project and the decision to permanently supplement the remaining funds into working capital [3][4]. - The cancellation of these accounts also leads to the termination of the corresponding tripartite/quadripartite supervision agreements [4].

Core Viewpoint - Awei Technology has experienced a decline in profitability despite its growth in the in vitro diagnostic field since its listing on June 16, 2021, with a market value decrease from 26.04 billion yuan to 14.23 billion yuan over four years [1][3][5] Business Overview - Awei Technology's main business includes the research, production, sales, and service of medical clinical testing analysis instruments and supporting in vitro diagnostic reagents and medical consumables [3] - The core product revenue structure shows that reagents account for the highest proportion at 53.44%, followed by instruments at 25.17% [3] Financial Performance - In 2021, Awei Technology achieved a net profit attributable to shareholders of 0.31 billion yuan, which decreased to 0.23 billion yuan by the end of the latest complete fiscal year in 2024, reflecting a cumulative profit growth decline of 26.97% [3] - The company has not reported any annual losses in the past four years, with profit growth occurring in three out of four years, representing a 75.0% success rate [3] - Revenue remained relatively stable, with 2.11 billion yuan in 2021 and 2.03 billion yuan in 2024, indicating a lack of growth momentum [3] Market Capitalization - Awei Technology reached a market capitalization peak of 30.94 billion yuan and a stock price of 45.5 yuan on June 16, 2021, but as of June 13, the market cap has decreased to 14.23 billion yuan, resulting in a market value loss of 16.71 billion yuan, or 54.02% [5]

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会召开情况 证券代码：688067 证券简称：爱威科技 公告编号：2025-020 爱威科技股份有限公司 第五届监事会第三次会议决议公告 （一）审议通过《关于公司使用暂时闲置自有资金进行现金管理的议案》 议案内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的 《爱威科技股份有限公司关于使用暂时闲置自有资金进行现金管理的公告》。 监事会认为：在确保正常经营所需资金及资金安全的前提下，公司本次使 用暂时闲置自有资金进行现金管理，有利于提高公司闲置自有资金利用率，增 加公司收益和股东回报，不存在损害公司及全体股东，特别是中小股东利益的 情形。综上，监事会同意公司本次使用暂时闲置自有资金进行现金管理事项。 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 爱威科技股份有限公司监事会 爱威科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开第五 届监事会第三次会议，本次会议应出席监事 3 人，实际出席监事 3 人。会议由 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-021 爱威科技股份有限公司 关于使用暂时闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日分别召开 第五届董事会第三次会议和第五届监事会第三次会议，审议通过《关于公司使 用暂时闲置自有资金进行现金管理的议案》，同意公司使用额度不超过 35,000 万元（含本数）的暂时闲置自有资金进行现金管理，自董事会审议通过之日起 12 个月内有效，在上述额度及决议有效期内，资金可以循环滚动使用。公司董 事会授权公司管理层在上述有效期和额度范围内行使该事项决策权并签署相关 合同文件，具体事项由公司财务部负责组织实施。现将相关情况公告如下： 一、本次使用闲置自有资金进行现金管理的基本情况 (一) 投资目的 在确保不影响自有资金安全和正常生产经营的前提下，公司拟使用暂时闲 置自有资金进行现金管理, 以提高公司资金使用效率，增加公司现金资产收益， 为公司及股东获取更多回报。 （ ...

第五届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688067 证券简称：爱威科技 公告编号：2025-020 爱威科技股份有限公司 2025 年 5 月 30 日 1 一、监事会召开情况 爱威科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开第五 届监事会第三次会议，本次会议应出席监事 3 人，实际出席监事 3 人。会议由 监事会主席段小霞女士主持，以现场方式召开。本次会议的通知、召开及审议 程序符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司使用暂时闲置自有资金进行现金管理的议案》 议案内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的 《爱威科技股份有限公司关于使用暂时闲置自有资金进行现金管理的公告》。 监事会认为：在确保正常经营所需资金及资金安全的前提下，公司本次使 用暂时闲置自有资金进行现金管理，有利于提高公司闲置自有资金利用率，增 加公司收益和股东回报，不存在损害公 ...

Core Viewpoint - The company aims to enhance its AI capabilities and product offerings while maintaining a strong focus on technological innovation and efficiency improvements in its operations [1][2]. Group 1: Company Strategy and Innovation - The company is committed to deepening its research in AI and expanding its product matrix, with a focus on technology innovation mechanisms [1]. - The company has accumulated a vast database of desensitized data based on real specimen images, which is a core resource that is difficult for competitors to replicate [2]. - In 2024, the company participated in the development of four group standards and authored four academic works, further solidifying its technological leadership [2]. Group 2: Financial Performance - In a challenging environment for the medical device industry, the company achieved growth in both revenue and net profit in 2024, demonstrating strong operational resilience [2]. - The company implemented cost-reduction and efficiency-enhancement measures across procurement, manufacturing, and R&D, leading to a decrease in product costs [2]. - The sales proportion of high-margin reagents and consumables has gradually increased, resulting in an overall improvement in gross margin compared to the previous year [2]. Group 3: Market Expansion and Product Development - The company has installed its testing instruments in over 6,000 hospitals nationwide, with nearly 8,000 units in use, which supports the growth of high-margin reagent sales [3]. - The company has launched multiple POCT product series covering various health areas, and these products are being sold through various channels including e-commerce platforms and clinics [3]. - The company is actively building third-party IVD laboratories and developing a smart healthcare platform aimed at serving grassroots markets [4].